naftopidil has been researched along with transforming growth factor beta in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, IJ | 1 |
| Murtola, TJ | 1 |
| Enomoto, Y; Fujimura, T; Fukuhara, H; Hirano, Y; Homma, Y; Kumano, S; Kume, H; Nishimatsu, H; Suzuki, M; Yamada, D | 1 |
3 other study(ies) available for naftopidil and transforming growth factor beta
| Article | Year |
|---|---|
Editorial comment from Dr Chen to reduction of prostate cancer incidence by naftopidil, an α1-adrenoceptor antagonist and transforming growth factor-β signaling inhibitor.
Topics: Adrenergic alpha-1 Receptor Antagonists; Humans; Male; Naphthalenes; Piperazines; Prostatic Neoplasms; Transforming Growth Factor beta | 2013 |
Editorial comment from Dr Murtola to reduction of prostate cancer incidence by naftopidil, an α1-adrenoceptor antagonist and transforming growth factor-β signaling inhibitor.
Topics: Adrenergic alpha-1 Receptor Antagonists; Humans; Male; Naphthalenes; Piperazines; Prostatic Neoplasms; Transforming Growth Factor beta | 2013 |
Reduction of prostate cancer incidence by naftopidil, an α1 -adrenoceptor antagonist and transforming growth factor-β signaling inhibitor.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Apoptosis; Cell Line, Tumor; HeLa Cells; Humans; Incidence; Male; Middle Aged; Multivariate Analysis; Naphthalenes; Piperazines; Proportional Hazards Models; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Signal Transduction; Sulfonamides; Tamsulosin; Transforming Growth Factor beta | 2013 |